|
|||
Epidemiologic Features
Pathological Features
Molecular Pathogenesis
Deregulated Growth Factor Signaling
Role of Stem Cells in Pathogenesis and Resistance to Therapy
Diagnosis
Clinical Presentation
Imaging
Treatment
General Medical Management
Specific Therapy for Newly Diagnosed Malignant Gliomas
Therapy for Anaplastic Gliomas
Therapy for Recurrent Malignant Gliomas
Investigational Therapies
Targeted Molecular Therapies
Antiangiogenic Agents
Other Therapies
Prognostic Factors
Summary
Source Information
From the Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital; and the Center for Neuro-Oncology, Dana–Farber Cancer Institute — both in Boston.
Address reprint requests to Dr. Wen at the Center for Neuro-Oncology, Dana–Farber/Brigham and Women's Cancer Center, SW430D, 44 Binney St., Boston, MA 02115, or at pwen@partners.org.
Related Letters:
Malignant Gliomas in Adults
Meyer M. A., Wen P. Y., Kesari S.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:1850, Oct 23, 2008.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |